

Role of Extracellular Adenosine in Acute Lung Injury

Acute lung injury (ALI) is a lung disease characterized by pulmonary edema and severe hypoxia. The past decade hosted a search for endogenous mechanisms controlling lung inflammation and pulmonary edema during ALI. As such, recent evidence indicates extracellular adenosine in orchestrating the resolution of pulmonary edema and inflammation during ALI.

Tobias Eckle,¹ Michael Koeppen,¹
and Holger K. Eltzschig^{1,2}

¹Department of Anesthesiology, Mucosal Inflammation Program, University of Colorado Denver, Aurora, Colorado; and
²Department of Anesthesiology and Intensive Care Medicine, Tübingen University Hospital, Tübingen, Germany
holger.eltzschig@ucdenver.edu

Acute lung injury (ALI) is a lung disease characterized by acute onset of hypoxemic respiratory failure with bilateral pulmonary edema in the absence of left heart failure (96). It is important to rule out left heart failure as a mechanism, because the treatment for pulmonary edema caused by congestive heart failure would be very different. Based on the degree of hypoxia as indicated by the gradient of arterial oxygen partial pressure (PaO₂) to the fraction of inspired oxygen (FiO₂), ALI is defined by a PaO₂/FiO₂ gradient below 300 mmHg. In its more severe form with a PaO₂/FiO₂ gradient below 200 mmHg, the term acute respiratory distress syndrome (ARDS) is used. From an etiological perspective, ALI can be caused by a diverse spectrum of mechanisms, including disorders directly involving the lungs such as pneumonia, aspiration of gastric content, or lung contusion. However, in many instances, ALI develops following an indirect injury to the lungs, for example, during sepsis or following severe trauma (96). Moreover, the transfusion of blood products is an important cause for ALI [transfusion-related ALI (TRALI)]. In fact, TRALI has been the leading cause of transfusion-related deaths in the USA (85). Despite optimal management consisting of aggressive treatment of the initiating cause, vigilant supportive care, and the prevention of nosocomial infections, mortality ranges between 35 and 60% (96). In fact, ~200,000 patients develop ALI annually in the USA, leading to 75,000 deaths and accounting for up to 3.6 million hospital days (78). The pathogenesis of ALI is characterized by the influx of a protein-rich edema fluid into the interstitial and intra-alveolar spaces as a consequence of increased permeability of the capillary-alveolar barrier. Molecular details of how capillary-alveolar leakage is caused and maintained during ALI are largely unknown, and studies on identifying its molecular or genetic basis (42) as well as linking molecular mechanisms with mechanical ventilation are currently areas of intense investigation (18, 65, 92). Particularly, studies that try to identify endogenous pathways to promote the resolution of pulmonary inflammation and injury hold the promise to identify novel therapeutic approaches to ALI, which are urgently needed (60, 80–82).

Consistent with this concept, many episodes of ALI are self-limiting and resolve spontaneously through unknown mechanisms. For example, patients undergoing major thoracic surgery for lung cancer suffer from ALI in <5% (61), open heart surgery with cardiopulmonary bypass <0.5% (66), or kidney transplantation <0.2% (84). Based on these clinical observations, studies are aimed to identify innate adaptive pathways that could dampen acute increases in the capillary-alveolar barrier, and attenuate or resolve lung inflammation. Some of these studies pointed toward the signaling molecule adenosine in endogenous lung protection during ALI. In the extracellular compartment, adenosine is produced from precursor nucleotides (ATP, ADP, and AMP) via enzymatic phosphohydrolysis. Adenosine can activate any of four G-protein-coupled adenosine receptors (ARs, A1AR, A2AAR, A2BAR, A3AR) and has been implicated as endogenous distress signal to balance inflammatory responses (33, 34, 45–47, 49) and to attenuate alveolar-capillary leakage (19, 20). In fact, recent studies suggest extracellular adenosine receptors, particularly the A2A and A2BAR, as a potential therapeutic target for the treatment of ALI.

Identification of Pulmonary-Epithelial-Derived Adenosine as Inhibitor of Capillary-Alveolar Leakage

Clinical observations indicate that ALI is a self-limiting disease with the tendency to resolve spontaneously in many instances. As such, a recent study cast a wide net to identify endogenous mediators that counterbalance increases in capillary-alveolar leakage during ALI. Because of lung failure and systemic hypoxia, most patients who experience ALI are intubated and require mechanical ventilation. To model mechanical ventilation, the authors of this study exposed pulmonary epithelial cells to cyclic mechanical stretch *in vitro* and studied the accumulation of mediators within the supernatant (FIGURE 1) (19). Following resolution via high-performance liquid chromatography (HPLC), the authors exposed individual fractions of the supernatant to an *in vitro* model of endothelial

barrier function. Indeed, the authors identified a single fraction of the supernatant from stretch-induced injury that diminished endothelial leakage. Subsequent analysis of size, stability, UV spectroscopy, and HPLC retention time demonstrated that the biologically active compound within that fraction was adenosine (19). Indeed, previous studies had indicated that extracellular adenosine can function as a signaling molecule that attenuates leakage through endothelial or epithelial barriers in the setting of acute inflammation or hypoxia (26, 29, 59, 70, 86, 87, 91–93). To confirm these *in vitro* findings from stretch-exposed pulmonary epithelial cells under *in vivo* conditions of ALI, the authors went on to utilize mechanical ventilation to induce lung injury (18). They exposed mice to mechanical ventilation at high inspiratory pressure levels over several hours and measured total pulmonary adenosine levels or adenosine concentrations within the bronchoalveolar fluid. Consistent with their initial *in vitro* studies, they found that adenosine levels were elevated in the lungs of mice or in the bronchoalveolar fluid following the induction of ALI (19). Taken together, these studies identified extracellular adenosine as a barrier protective factor within the supernatant of pulmonary epithelial cells exposed to cyclic mechanical stretch *in vitro* or within the bronchoalveolar fluid of lungs exposed to ALI (19).

Extracellular Nucleotide Release

In the extracellular space, adenosine mainly stems from phosphohydrolysis of precursor nucleotides,

specifically ATP and ADP. Such nucleotides are released from multiple cell types (69). Studies have shown that, during acute injury (e.g., by hypoxia or inflammation), extracellular nucleotide levels are dramatically increased (22, 39, 40, 55). These increases in extracellular nucleotide levels are mainly due to release of ATP or ADP from the intracellular to the extracellular space (25, 26). One has to keep in mind that intracellular ATP concentrations are relatively high, ranging from 2 to 6 mM (69). As such, leakage of intracellular ATP stores from injured cells during ALI represents an important source for elevating extracellular ATP levels. For example, exposure of pulmonary endo- or epithelial cells to oxidative stress or to hyperoxia results in a rapid release of ATP (2, 3, 36). Previous studies have also demonstrated regulated mechanisms of cellular ATP release (25, 26, 28, 31). As such, platelets can release nucleotides (particularly in the form of ADP) into the extracellular space on activation by ADP or collagen (37, 97). Moreover, PMNs that accumulate in pulmonary tissues during ALI represent an additional source for extracellular nucleotides. In fact, a recent study showed a critical role of PMN-dependent ATP release in directed movement of PMNs. Such purinergic chemotaxis appears to involve ATP release on the leading edge of the PMN (10, 63). Studies on the mechanism of PMN-dependent ATP release have revealed an important role of the pore-forming hemichannel connexin 43 (Cx43) (25). Although PMN-dependent ATP release occurs on activation with inflammatory stimuli, pharmacological inhibition of Cx43-dependent transport with specific connexin-mimetic peptides completely abolished the




FIGURE 1. Identification of adenosine as barrier-protective factor in the supernatant of pulmonary epithelial cells during stretch-injury

A recent study identified accumulation of extracellular adenosine within the supernatant of stretched pulmonary epithelial cells as barrier protective mediator (19). For this purpose, the authors exposed Calu-3 human bronchial epithelial cells to cyclic mechanical stretch over 48 h. Supernatants were harvested, fractionated by HPLC, and tested for bioactivity for endothelial barrier protection. A single fraction was found to be biologically active, and subsequent studies based on molecular size, stability, HPLC retention time, and UV spectroscopy determined adenosine as the biologically active compound.

Downloaded from <http://physiologyonline.physiology.org/> by 10.220.33.6 on May 22, 2017

rapid and robust ATP-release from stimulated PMN. These pharmacological studies were confirmed in genetic models, where neutrophils isolated from mice with induced gene-deletion of Cx43 had attenuated ATP-release on inflammatory activation (25). Taken together, such studies indicate the likelihood that extracellular levels of nucleotides, particularly ATP and ADP, are elevated during ALI.

Extracellular Nucleotide Signaling During Lung Injury

There are two principal pathways that extracellular nucleotides can be involved in. First, they can activate extracellular nucleotide receptors (so-called P2 receptors), or they can be rapidly hydrolyzed to extracellular AMP and adenosine. Although there is only very little known about the role of AMP as a signaling molecule, ATP or ADP signaling has been implemented in lung disease. As such, ATP or ADP can signal through G-protein-coupled receptors (P2Y receptors) or through ligand-gated ion channels (P2X receptors). Although their role in ALI has yet to be better defined, some studies suggest a detrimental role in lung inflammation and asthma. As such, a very elegant study by Idzko et al. showed that extracellular ATP triggers and maintains asthmatic airway inflammation by activating dendritic cells (53). The authors showed that allergen challenge causes acute accumulation of ATP in the airways of asthmatic subjects and mice with experimentally induced asthma. All the cardinal features of

asthma were abrogated when lung ATP levels were locally neutralized using apyrase or when mice were treated with broad-spectrum P2-receptor antagonists. As such, this study shows that ATP signaling has a key role in allergen-driven lung inflammation (53).

Enzymatic Nucleotide Phosphohydrolysis Via CD39 and CD73

Extracellular nucleotides in the form of ATP or ADP are rapidly hydrolyzed in the extracellular space to adenosine. In fact, extracellular adenosine generation from precursor nucleotides occurs in a two-step enzymatic reaction. First, extracellular ATP and ADP are converted to AMP (FIGURE 2). This reaction is catalyzed by the ecto-nucleotide-diphosphohydrolase (E-NTPDase) 1, also known as ecto-apyrase or CD39 (76). Research work from the laboratory of Simon C. Robson indicates that CD39 is expressed ubiquitously on endothelia, epithelia, or inflammatory cells (4, 14, 25–27, 30, 43) and rapidly catalyzes the generation of AMP from ATP or ADP. The second step of extracellular adenosine generation is catalyzed by the ecto-5'-nucleotidase, also known as CD73, which is a GPI anchored ecto-enzyme catalyzing the conversion of extracellular AMP into adenosine (FIGURE 3) (12). Research work from the laboratories of Linda Thompson and Sean Colgan demonstrates that the ecto-5'-nucleotidase is expressed ubiquitously with high enzymatic activity in pulmonary tissues (93). Localized on the extracellular surface of endothelial or epithelial cells, CD73 rapidly converts AMP to adenosine (22, 39, 91, 93). During acute injury (e.g., hypoxia), extracellular adenosine production via CD39 and CD73 are increased (19). For example, recent studies on the influence of hypoxia or ischemia on CD39 or CD73 transcript, protein, and enzymatic function found that both enzymes are rapidly induced by limited oxygen availability (22, 26, 27, 39–41, 46, 49, 55, 91). Although the transcriptional pathways of CD39-dependent induction during hypoxia involves the transcription factor SP1 (27), transcriptional mechanisms of hypoxia-dependent induction of CD73 are coordinated by hypoxia-inducible factor (HIF)-1 (91). As such, epithelia or endothelia preexposed to hypoxia show dramatic increases in their capacity to hydrolyze extracellular ATP to adenosine (26, 91). Such studies also highlight the role of hypoxia-inducible factor in attenuating mucosal inflammation during inflammation or limited oxygen availability (13, 21, 24, 44, 54, 57, 67, 68, 75, 77, 91).

siRNA approaches, or studies in gene-targeted mice for CD39 or CD73 confirmed, their importance for the increased phosphohydrolysis during hypoxia (22, 26, 27, 39–41, 46, 49, 55, 91). As such, several studies utilized an in vivo model of ambient hypoxia with exposure of mice to 8% oxygen over 4 h (24, 67, 68).




FIGURE 2. Pulmonary ecto-apyrase (CD39) in extracellular adenosine generation

During conditions of acute lung injury (ALI), extracellular nucleotides in the form of ATP (and also ADP; not shown in the figure) are released by different cell types. The ecto-apyrase (CD39), which is expressed on pulmonary epithelial cells, vascular endothelia, or immune cells, rapidly converts extracellular ATP to AMP. This transcriptionally controlled metabolic pathway represents the first step for the extracellular generation of adenosine during ALI.

Although hypoxia elicited increases in vascular leakage, inflammatory cell accumulation, and pulmonary edema in littermate controls, these responses were dramatically enhanced in *cd39*^{-/-} or *cd73*^{-/-} mice (26, 93), thereby confirming an *in vivo* role of CD39- and CD73-dependent nucleotide phosphohydrolysis and adenosine signaling in protecting the alveolar-capillary barrier function and balancing pulmonary inflammation during hypoxia (26, 29).

Other studies examined the role of CD39 and CD73 in models of ALI. Utilizing mechanical ventilation to model ALI, the authors found induction of pulmonary CD39 and CD73 levels (19). Moreover, these studies observed pressure- and time-dependent increases in pulmonary edema and inflammation in *cd39*^{-/-} mice during ALI compared with control animals. Similarly, pharmacological inhibition or targeted gene deletion of *cd73* was associated with increased symptom severity of ventilator-induced ALI. Reconstitution of *cd39*^{-/-} or *cd73*^{-/-} mice with soluble apyrase (converts ATP/ADP to AMP) or 5'-nucleotidase (converts AMP to adenosine), respectively, reversed such increases. In addition, ALI was significantly attenuated and survival improved after intraperitoneal treatment of wild-type mice with soluble apyrase or 5'-nucleotidase.

Similar to these studies in ALI, a very elegant study from the research team of Michael Blackburn found that adenosine levels are elevated in the lungs of mice injured by the drug bleomycin (95). In addition, increased activity of ecto-5'-nucleotidase (CD73) was found in the lungs in conjunction with adenosine elevations. To determine the contribution of CD73 to the generation of adenosine in the lung, *cd73*^{-/-} mice were subjected to bleomycin challenges, which represents a more chronic type of lung injury compared with studies utilizing hypoxia, mechanical ventilation, or LPS inhalation to induce lung injury (17–20, 74, 94). Results demonstrated that *cd73*^{-/-} mice challenged with bleomycin no longer accumulated adenosine in their lungs, suggesting that the primary means of adenosine production following bleomycin injury resulted from the release and subsequent dephosphorylation of adenine nucleotides. *Cd73*^{-/-} mice challenged with bleomycin exhibited enhanced pulmonary inflammation and fibrosis as well as exaggerated expression of proinflammatory and profibrotic mediators in the lung. Intranasal instillations of exogenous nucleotidase restored the ability of lungs of *cd73*^{-/-} mice to accumulate adenosine following bleomycin challenge. Furthermore, these treatments were associated with a decrease in pulmonary inflammation and fibrosis. Wild-type mice challenged with bleomycin and supplemented with exogenous nucleotidase also exhibited reduced inflammation. These findings indicate CD73-dependent adenosine production as anti-inflammatory pathways in bleomycin-induced lung injury, a murine model for pulmonary fibrosis and chronic forms of lung disease (95).

Other studies examined the role of CD39 and CD73 in mediating pulmonary neutrophil (PMN) transmigration during lipopolysaccharide (LPS)-induced lung injury. Similar to ALI induced by mechanical ventila-

“Taken together, these data reveal an important role for CD39- and CD73-dependent generation of extracellular adenosine during ventilator-, LPS-, or bleomycin-induced forms of lung injury.”

tion, pulmonary CD39 and CD73 transcript levels were elevated following LPS exposure *in vivo*. Moreover, LPS-induced accumulation of PMN into the lungs was enhanced in gene-targeted mice for *cd39* or *cd73*, particularly into the interstitial and intra-alveolar compartment. Such increases in PMN trafficking were accompanied by corresponding changes in alveolar-capillary leakage. Similarly, inhibition of extracellular nucleotide phosphohydrolysis with the nonspecific ecto-nucleoside-triphosphate-diphosphohydrolases inhibitor POM-1 confirmed increased pulmonary PMN accumulation in wild-type, but not in gene-targeted mice for *cd39* or *cd73*. Taken together, these data reveal an important role for CD39- and CD73-dependent generation of extracellular adenosine during ventilator-, LPS-, or bleomycin-induced forms of lung injury. In addition, these studies suggest




FIGURE 3. Ecto-5'-nucleotidase (CD73) in extracellular adenosine production of the lungs

The ecto-5'-nucleotidase (CD73) is a GPI-anchored enzyme localized exclusively on the extracellular surface and rapidly converts extracellular AMP to adenosine. The lungs express high levels of CD73, including pulmonary epithelia, vascular endothelia, or immune cells. As such, CD73-dependent adenosine generation represents the pace-maker in extracellular adenosine production during acute lung injury.

their soluble compounds (e.g., soluble nucleotidase or apyrase) as a therapeutic strategy for improving the capillary alveolar barrier function, attenuating inflammatory cell trafficking into the lungs, or dampening fibrotic changes (19, 74, 95).

Adenosine Signaling During ALI

In the extracellular space, adenosine mainly serves as signaling molecule that can activate four adenosine receptors (ARs) (33). Four different receptors have been described (A1AR, A2AAR, A2BAR, and A3AR; **FIGURE 4**) (22, 58, 79, 90). Although ARs result in different biological functions, extracellular adenosine signaling effects depend on the expression of individual ARs on the extracellular surface (17, 20, 22, 26, 38, 45, 56, 77). ARs contain seven transmembrane-spanning domains and are coupled to intracellular GTP-binding proteins, utilizing intracellular cyclic AMP (cAMP) as second messenger (23, 50, 51). As such, AR signaling occurs through changes in adenylyl cyclase activity, resulting in subsequent alteration of intracellular cAMP levels as second messenger (33). In general terms, the A1AR and the A3AR are thought to attenuate cAMP. In contrast, the A2AAR and the A2BAR are associated with cAMP elevations (23, 33, 50, 51, 62). In addition to alerting cAMP levels, adenosine signaling has also been implemented in modulating intracellular calcium levels (33, 50, 51).

Previous studies compared expressional levels of ARs in the lungs of mice (64). These studies demonstrated

the highest expressional levels of the A2BAR, followed by the A2AAR (64). Other studies found increased levels of A2BAR expression with large tidal volume ventilation (15) or following the induction of ALI by mechanical ventilation (18). Studies using an A2BAR reporter mouse model revealed high expression of the A2BAR in murine type II alveolar epithelial cells (8). In addition, other studies using the same A2BAR reporter model identified a vascular A2BAR expression pattern (9, 38, 98, 99).

A2A Adenosine Receptors

Although there is only little known about the role of the A1AR or the A3AR in lung injury, several studies point toward a protective role of A2A or A2BAR signaling during ALI. One of the first studies to provide genetic *in vivo* evidence for adenosine-dependent protection from excessive inflammation in different models utilized gene-targeted mice for the A2AAR (70). Subthreshold doses of an inflammatory stimulus that caused minimal tissue damage in wild-type mice were sufficient to induce extensive tissue damage, more prolonged and higher levels of pro-inflammatory cytokines, and death in *A2AAR*^{-/-} mice. Similar observations were made in studies of three different models of inflammation and liver damage as well as during bacterial endotoxin-induced septic shock (70). These studies indicate that the A2AAR plays a critical part of the physiological negative feedback mechanism for limitation and termination of tissue-specific and systemic inflammatory responses (70). Other studies confirmed a role for the A2AAR receptor in lung protection during ALI. Several studies identified a role of A2AAR signaling predominantly via activation of myeloid A2AARs in different models of lung protection, including LPS-induced lung injury (73), or in models of lung injury induced by pulmonary ischemia reperfusion injury (83) or lung transplantation (35). This is also consistent with studies from the laboratory of Joel Linden demonstrating myeloid A2AARs in attenuating myocardial ischemia reperfusion injury (101).

A very elegant study by Thiel et al., in a team led by Michail Sitkovsky, tested the hypothesis that oxygenation weakens a tissue-protecting mechanism triggered by hypoxia. This study is based on the observation that hypoxia triggers signaling pathways mediated by the A2AAR that attenuate lung inflammation and tissue damage (92). This hypoxia-driven pathway protects the lungs from the toxic effects of overactive immune cells such as neutrophils (92). Using a mouse model of ALI induced by bacterial infection, Thiel et al. exposed one group of mice to 100% oxygen, mimicking therapeutic oxygenation, and left another group at normal ambient levels (21% oxygen) (92). Five times more mice died after receiving 100% oxygen than died breathing normal oxygen levels. Mice given 60% oxygen—which is considered clinically safe—got worse but did not die. Hypoxia protects




FIGURE 4. Extracellular adenosine signaling during acute lung injury Adenosine (A) signaling during acute lung injury can involve any of four adenosine receptors: the A1, A2A, A2B, and A3 receptors. Based on transcriptional profiling studies, highest expression levels were found for the A2A and the A2B adenosine receptor. In addition, expression of both receptors can be increased under conditions of hypoxia, cyclic mechanical stretch, or acute inflammation. As such, several studies have provided evidence for attenuation of lung inflammation or pulmonary edema via A2A or A2B adenosine signaling.

against lung damage, the authors conclude, by working through the A2AAR signaling pathway to control inflammation. Above-normal oxygen levels interrupt this anti-inflammatory pathway, paving the way for further lung injury (52a). Consistent with this work, a very recent study demonstrated a specific transcriptional pathway for HIF-2 α in the control of the A2AAR during hypoxia (1). Taken together, such studies indicate that high levels of inspired oxygen, as may be required to provide sufficient tissue oxygenation in patients suffering from ALI, may weaken the local tissue hypoxia-driven and AR-mediated anti-inflammatory mechanism and thereby further exacerbate lung injury (23, 92).

A2B Adenosine Receptors

Other studies found an important contribution of signaling via the A2BAR in lung protection from ALI. First evidence comes from studies of hypoxia-induced vascular leakage, lung inflammation, and pulmonary edema (17). Here, the authors exposed gene-targeted mice for each individual AR to ambient hypoxia (4% oxygen over 4 h) and assessed pulmonary edema and vascular leakage. The authors found a selective phenotype in gene-targeted mice for the A2BAR. Moreover, treatment with a highly specific A2BAR agonist (BAY 60-6583) (22) attenuated hypoxia-induced alveolar-capillary leakage. Further studies examined the contribution of endogenous adenosine signaling to attenuation of VILI or endotoxin-induced lung injury (20). Initial profiling studies using gene-targeted mice for the A1, A2A, A2B, or A3AR revealed that genetic deletion of the A2BAR was specifically associated with reduced survival time and increased pulmonary albumin leakage (5.3 \pm 0.15-fold) during ALI. Studies in wild-type mice showed that treatment with A2BAR-selective antagonist PSB1115 resulted in enhanced pulmonary inflammation, edema, and attenuated gas-exchange, whereas treatment with the A2BAR-agonist BAY 60-6583 (22) attenuated VILI. Studies in bone marrow chimeric A2BAR mice demonstrated pulmonary A2BARs in VILI-induced albumin leakage and edema, whereas increases in pulmonary inflammation were, at least in part, bone marrow mediated. Measurement of alveolar fluid clearance indicated that A2BAR signaling enhanced amiloride-sensitive fluid transport via elevation of pulmonary cAMP levels, similar to beta-adrenergic agonist stimulation, suggesting that A2BAR-agonist treatment protects by drying out the lungs during VILI (20). Taken together, such studies demonstrate that extracellular adenosine production via CD39 and CD73, in conjunction with A2A or A2BAR signaling, represents an endogenous pathway to protect the lungs from pulmonary edema and excessive inflammation (19, 20, 23).

Chronic Elevation of Extracellular Adenosine Levels

In contrast to the beneficial effects of increased adenosine production and signaling during ALI, there is some evidence suggesting a potentially detrimental role of chronically elevated adenosine levels (5, 11, 88, 89). For example, levels of adenosine are increased in the lungs of asthmatics (16) and correlate with the degree of inflammatory insult (52). At present, it is not entirely clear whether such elevations of adenosine are part of a protective pathway to dampen lung inflammation or play a provocative role of adenosine in asthma or chronic obstructive pulmonary disease (32). For example, mice incapable of extracellular adenosine generation (*cd73*^{-/-} mice) exhibit a more severe phenotype in bleomycin-induced lung injury, indicating a protective role of extracellular adenosine signaling in this chronic model of lung disease (95).

In contrast, adenosine-deaminase (ADA)-deficient mice develop signs of chronic lung inflammation in association with dramatically elevated pulmonary adenosine levels. In fact, ADA-deficient mice die within weeks after birth from severe respiratory distress (7), and pharmacological studies suggest that attenuation of adenosine signaling through the A2BAR may reverse the severe pulmonary phenotypes in ADA-deficient mice (7, 89). To address these findings on a genetic level, the research team of Michael Blackburn recently examined the contribution of A2BAR signaling in this model by utilizing a genetic approach by generating ADA/A2BAR double-knockout mice (104). The authors' initial hypothesis was that genetic removal of the A2BAR from ADA-deficient mice would lead to diminished pulmonary inflammation and damage. Unexpectedly, ADA/A2BAR double-knockout mice exhibited enhanced pulmonary inflammation and airway destruction. Marked loss of pulmonary barrier function and excessive airway neutrophilia are thought to contribute to the enhanced tissue damage observed. These findings support an important protective role for A2BAR signaling during acute stages of lung disease (104).

Summary and Future Challenges

This review highlights the role of extracellular adenosine production and signaling as a transcriptionally controlled metabolic pathways in endogenous lung protection from acute injury. Many of these studies indicate that targeting extracellular adenosine production and signaling may represent a novel therapeutic approach for the treatment of lung inflammation and pulmonary edema during ALI. From a clinical perspective, new approaches for treating patients suffering from ALI are urgently needed for several reasons. First, ALI is among the leading causes for morbidity and mortality of critically ill patients (78). In

addition, treatment approaches for ALI are extremely limited and focus on elimination of potential causes, in conjunction with supportive therapy (96). In fact, no specific therapy for attenuating pulmonary edema and lung inflammation during ALI has been established as an effective clinical form of therapy (102, 103).

It is important to point out that the studies described in the present review were carried out in animal models, in fact, most of them in mice. Therefore, it will be a critical challenge for the future to translate these findings from mice to humans. In addition, potentially unwanted side effects of pharmacological elevations of extracellular adenosine levels or specific AR agonists have to be addressed. For example, such unwanted side effects could include alterations in blood pressure, heart rate, or sleep-awake cycle (100), fatty liver disease (71), or chronic forms of lung disease (89) or involve platelet function, thromboregulation, or bleeding (30, 48, 72). ■

The authors acknowledge Shelley A. Eltzschig for the artwork during manuscript preparation.

The present review is supported by National Heart, Lung, and Blood Institute Grant R01-HL-092188 to H. K. Eltzschig and T. Eckle, Foundation for Anesthesia Education and Research Grants to T. Eckle and H. K. Eltzschig, and American Heart Association Grant to T. Eckle and H. K. Eltzschig.

References

1. Ahmad A, Ahmad S, Glover L, Miller SM, Shannon JM, Guo X, Franklin WA, Bridges JP, Schaack JB, Colgan SP, White CW. Adenosine A2A receptor is a unique angiogenic target of HIF-2alpha in pulmonary endothelial cells. *Proc Natl Acad Sci USA* 106: 10684–10689, 2009.
2. Ahmad S, Ahmad A, Ghosh M, Leslie CC, White CW. Extracellular ATP-mediated signaling for survival in hyperoxia-induced oxidative stress. *J Biol Chem* 279: 16317–16325, 2004.
3. Ahmad S, Ahmad A, McConville G, Schneider BK, Allen CB, Manzer R, Mason RJ, White CW. Lung epithelial cells release ATP during ozone exposure: signaling for cell survival. *Free Radic Biol Med* 39: 213–226, 2005.
4. Beldi G, Wu Y, Sun X, Imai M, Enjyoji K, Cszmadia E, Candinias D, Erb L, Robson SC. Regulated catalysis of extracellular nucleotides by vascular CD39/ENTPD1 is required for liver regeneration. *Gastroenterology* 135: 1751–1760, 2008.
5. Blackburn MR. Too much of a good thing: adenosine overload in adenosine-deaminase-deficient mice. *Trends Pharmacol Sci* 24: 66–70, 2003.
7. Blackburn MR, Volmer JB, Thrasher JL, Zhong H, Crosby JR, Lee JJ, Kellems RE. Metabolic consequences of adenosine deaminase deficiency in mice are associated with defects in alveogenesis, pulmonary inflammation, and airway obstruction. *J Exp Med* 192: 159–170, 2000.
8. Cagnina RE, Ramos SI, Marshall MA, Wang G, Frazier CR, Linden J. Adenosine A2B receptors are highly expressed on murine type II alveolar epithelial cells. *Am J Physiol Lung Cell Mol Physiol* 297: L467–L474, 2009.
9. Chen H, Yang D, Carroll SH, Eltzschig HK, Ravid K. Activation of the macrophage A2b adenosine receptor regulates tumor necrosis factor-alpha levels following vascular injury. *Exp Hematol* 37: 533–538, 2009.
10. Chen Y, Corriden R, Inoue Y, Yip L, Hashiguchi N, Zinkernagel A, Nizet V, Insel PA, Junger WG. ATP release guides neutrophil chemotaxis via P2Y2 and A3 receptors. *Science* 314: 1792–1795, 2006.

11. Chunn JL, Molina JG, Mi T, Xia Y, Kellems RE, Blackburn MR. Adenosine-dependent pulmonary fibrosis in adenosine deaminase-deficient mice. *J Immunol* 175: 1937–1946, 2005.
12. Colgan SP, Eltzschig HK, Eckle T, Thompson LF. Physiological roles of 5'-ectonucleotidase (CD73). *Purinergic Signalling* 2: 351–360, 2006.
13. Cummins EP, Seeballuck F, Keely SJ, Mangan NE, Callanan JJ, Fallon PG, Taylor CT. The hydroxylase inhibitor dimethyloxalylglycine is protective in a murine model of colitis. *Gastroenterology* 134: 156–165, 2008.
14. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, Chen JF, Enjyoji K, Linden J, Oukka M, Kuchroo VK, Strom TB, Robson SC. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. *J Exp Med* 204: 1257–1265, 2007.
15. Douillet CD, Robinson WP, 3rd Zarzaur BL, Lazarowski ER, Boucher RC, Rich PB. Mechanical ventilation alters airway nucleotides and purinoceptors in lung and extrapulmonary organs. *Am J Respir Cell Mol Biol* 32: 52–58, 2005.
16. Driver AG, Kukoly CA, Ali S, Mustafa SJ. Adenosine in bronchoalveolar lavage fluid in asthma. *Am Rev Respir Dis* 148: 91–97, 1993.
17. Eckle T, Faigle M, Grenz A, Laucher S, Thompson LF, Eltzschig HK. A2B adenosine receptor dampens hypoxia-induced vascular leak. *Blood* 111: 2024–2035, 2008.
18. Eckle T, Fullbier L, Grenz A, Eltzschig HK. Usefulness of pressure-controlled ventilation at high inspiratory pressures to induce acute lung injury in mice. *Am J Physiol Lung Cell Mol Physiol* 295: L718–L724, 2008.
19. Eckle T, Fullbier L, Wehrmann M, Khoury J, Mittelbronn M, Ibla J, Rosenberger P, Eltzschig HK. Identification of ectonucleotidases CD39 and CD73 in innate protection during acute lung injury. *J Immunol* 178: 8127–8137, 2007.
20. Eckle T, Grenz A, Laucher S, Eltzschig HK. A2B adenosine receptor signaling attenuates acute lung injury by enhancing alveolar fluid clearance in mice. *J Clin Invest* 118: 3301–3315, 2008.
21. Eckle T, Kohler D, Lehmann R, El Kasmí KC, Eltzschig HK. Hypoxia-inducible factor-1 is central to cardioprotection: a new paradigm for ischemic preconditioning. *Circulation* 118: 166–175, 2008.
22. Eckle T, Krahn T, Grenz A, Kohler D, Mittelbronn M, Ledent C, Jacobson MA, Osswald H, Thompson LF, Unertl K, Eltzschig HK. Cardioprotection by ecto-5'-nucleotidase (CD73) and A2B adenosine receptors. *Circulation* 115: 1581–1590, 2007.
23. Eltzschig HK. Adenosine: an old drug newly discovered. *Anesthesiology*. In press.
24. Eltzschig HK, Abdulla P, Hoffman E, Hamilton KE, Daniels D, Schonfeld C, Loffler M, Reyes G, Duzsenko M, Karhausen J, Robinson A, Westerman KA, Coe IR, Colgan SP. HIF-1-dependent repression of equilibrative nucleoside transporter (ENT) in hypoxia. *J Exp Med* 202: 1493–1505, 2005.
25. Eltzschig HK, Eckle T, Mager A, Kuper N, Karcher C, Weissmuller T, Boengler K, Schulz R, Robson SC, Colgan SP. ATP release from activated neutrophils occurs via connexin 43 and modulates adenosine-dependent endothelial cell function. *Circ Res* 99: 1100–1108, 2006.
26. Eltzschig HK, Ibla JC, Furuta GT, Leonard MO, Jacobson KA, Enjyoji K, Robson SC, Colgan SP. Coordinated adenine nucleotide phosphohydrolysis and nucleoside signaling in posthypoxic endothelium: role of ectonucleotidases and adenosine A2B receptors. *J Exp Med* 198: 783–796, 2003.
27. Eltzschig HK, Kohler D, Eckle T, Kong T, Robson SC, Colgan SP. Central role of Sp1-regulated CD39 in hypoxia/ischemia protection. *Blood* 113: 224–232, 2009.
28. Eltzschig HK, Macmanus CF, Colgan SP. Neutrophils as sources of extracellular nucleotides: functional consequences at the vascular interface. *Trends Cardiovasc Med* 18: 103–107, 2008.
29. Eltzschig HK, Thompson LF, Karhausen J, Cotta RJ, Ibla JC, Robson SC, Colgan SP. Endogenous adenosine produced during hypoxia attenuates neutrophil accumulation: coordination by extracellular nucleotide metabolism. *Blood* 104: 3986–3992, 2004.

30. Enjyoji K, Sevigny J, Lin Y, Frenette PS, Christie PD, Esch JS, 2nd Imai M, Edelberg JM, Rayburn H, Lech M, Beeler DL, Csizmadia E, Wagner DD, Robson SC, Rosenberg RD. Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation. *Nat Med* 5: 1010–1017, 1999.
31. Faigle M, Seessle J, Zug S, El Kasmi KC, Eltzschig HK. ATP release from vascular endothelia occurs across Cx43 hemichannels and is attenuated during hypoxia. *PLoS ONE* 3: e2801, 2008.
32. Fozard JR, Hannon JP. Adenosine receptor ligands: potential as therapeutic agents in asthma and COPD. *Pulm Pharmacol Ther* 12: 111–114, 1999.
33. Fredholm BB. Adenosine, an endogenous distress signal, modulates tissue damage and repair. *Cell Death Differ* 14: 1315–1323, 2007.
34. Frick JS, MacManus CF, Scully M, Glover LE, Eltzschig HK, Colgan SP. Contribution of adenosine A2B receptors to inflammatory parameters of experimental colitis. *J Immunol* 182: 4957–4964, 2009.
35. Gazoni LM, Laubach VE, Mulloy DP, Bellizzi A, Unger EB, Linden J, Ellman PI, Lisle TC, Kron IL. Additive protection against lung ischemia-reperfusion injury by adenosine A2A receptor activation before procurement and during reperfusion. *J Thorac Cardiovasc Surg* 135: 156–165, 2008.
36. Gerasimovskaya EV, Ahmad S, White CW, Jones PL, Carpenter TC, Stenmark KR. Extracellular ATP is an autocrine/paracrine regulator of hypoxia-induced adventitial fibroblast growth. Signaling through extracellular signal-regulated kinase-1/2 and the Egr-1 transcription factor. *J Biol Chem* 277: 44638–44650, 2002.
37. Gordon JL. Extracellular ATP: effects, sources and fate. *Biochem J* 233: 309–319, 1986.
38. Grenz A, Osswald H, Eckle T, Yang D, Zhang H, Tran ZV, Klingel K, Ravid K, Eltzschig HK. The reno-vascular A2B adenosine receptor protects the kidney from ischemia. *PLoS Medicine* 5: e137, 2008.
39. Grenz A, Zhang H, Eckle T, Mittelbronn M, Wehrmann M, Kohle C, Kloor D, Thompson LF, Osswald H, Eltzschig HK. Protective role of ecto-5'-nucleotidase (CD73) in renal ischemia. *J Am Soc Nephrol* 18: 833–845, 2007.
40. Grenz A, Zhang H, Hermes M, Eckle T, Klingel K, Huang DY, Muller CE, Robson SC, Osswald H, Eltzschig HK. Contribution of E-NTPDase1 (CD39) to renal protection from ischemia-reperfusion injury. *FASEB J* 21: 2863–2873, 2007.
41. Grenz A, Zhang H, Weingart J, von Wietersheim S, Eckle T, Schnermann JB, Kohle C, Kloor D, Gleiter CH, Vallon V, Eltzschig HK, Osswald H. Lack of effect of extracellular adenosine generation and signalling on renal erythropoietin secretion during hypoxia. *Am J Physiol Renal Physiol* 293: F1501–F1511, 2007.
42. Grigoryev DN, Finigan JH, Hassoun P, Garcia JG. Science review: searching for gene candidates in acute lung injury. *Crit Care* 8: 440–447, 2004.
43. Guckelberger O, Sun XF, Sevigny J, Imai M, Kaczmarek E, Enjyoji K, Kruskal JB, Robson SC. Beneficial effects of CD39/ecto-nucleoside triphosphate diphosphohydrolase-1 in murine intestinal ischemia-reperfusion injury. *Thromb Haemost* 91: 576–586, 2004.
44. Haeberle HA, Durrstein C, Rosenberger P, Hosakote YM, Kuhlicke J, Kempf VA, Garofalo RP, Eltzschig HK. Oxygen-independent stabilization of hypoxia inducible factor (HIF)-1 during RSV infection. *PLoS ONE* 3: e3352, 2008.
45. Hart M, Jacobi B, Schittenhelm J, Henn M, Eltzschig HK. A2B adenosine receptor signaling provides potent protection during intestinal ischemia/reperfusion injury. *J Immunol*. In press.
46. Hart ML, Henn M, Kohler D, Kloor D, Mittelbronn M, Gorzolla IC, Stahl GL, Eltzschig HK. Role of extracellular nucleotide phosphohydrolysis in intestinal ischemia-reperfusion injury. *FASEB J* 22: 2784–2797, 2008.
47. Hart ML, Jacobi B, Schittenhelm J, Henn M, Eltzschig HK. Cutting edge: A2B adenosine receptor signaling provides potent protection during intestinal ischemia/reperfusion injury. *J Immunol* 182: 3965–3968, 2009.
48. Hart ML, Kohler D, Eckle T, Kloor D, Stahl GL, Eltzschig HK. Direct treatment of mouse or human blood with soluble 5'-nucleotidase inhibits platelet aggregation. *Arterioscler Thromb Vasc Biol* 28: 1477–1483, 2008.
49. Hart ML, Much C, Gorzolla IC, Schittenhelm J, Kloor D, Stahl GL, Eltzschig HK. Extracellular adenosine production by ecto-5'-nucleotidase protects during murine hepatic ischemic preconditioning. *Gastroenterology* 135: 1739–1750 e1733, 2008.
50. Hasko G, Csoka B, Nemeth ZH, Vizi ES, Pacher P. A(2B) adenosine receptors in immunity and inflammation. *Trends Immunol* 30: 263–270, 2009.
51. Hasko G, Linden J, Cronstein B, Pacher P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. *Nat Rev Drug Discov* 7: 759–770, 2008.
52. Huszar E, Vass G, Vizi E, Csoma Z, Barat E, Molnar Vilagos G, Herjavec I, Horvath I. Adenosine in exhaled breath condensate in healthy volunteers and in patients with asthma. *Eur Respir J* 20: 1393–1398, 2002.
- 52a. Hypoxia to the rescue: when oxygen therapies backfire. *PLoS Biol* 3: e211, 2005.
53. Idzko M, Hammad H, van Nimwegen M, Kool M, Willart MA, Muskens F, Hoogsteden HC, Luttmann W, Ferrari D, Di Virgilio F, Virchow JC Jr, Lambrecht BN. Extracellular ATP triggers and maintains asthmatic airway inflammation by activating dendritic cells. *Nat Med* 13: 913–919, 2007.
54. Karhausen J, Furuta GT, Tomaszewski JE, Johnson RS, Colgan SP, Haase VH. Epithelial hypoxia-inducible factor-1 is protective in murine experimental colitis. *J Clin Invest* 114: 1098–1106, 2004.
55. Kohler D, Eckle T, Faigle M, Grenz A, Mittelbronn M, Laucher S, Hart ML, Robson SC, Muller CE, Eltzschig HK. CD39/ectonucleoside triphosphate diphosphohydrolase 1 provides myocardial protection during cardiac ischemia/reperfusion injury. *Circulation* 116: 1784–1794, 2007.
56. Kong T, Westerman KA, Faigle M, Eltzschig HK, Colgan SP. HIF-dependent induction of adenosine A2B receptor in hypoxia. *FASEB J* 20: 2242–2250, 2006.
57. Kuhlicke J, Frick JS, Morote-Garcia JC, Rosenberger P, Eltzschig HK. Hypoxia inducible factor (HIF)-1 coordinates induction of Toll-like receptors TLR2 and TLR6 during hypoxia. *PLoS ONE* 2: e1364, 2007.
58. Ledent C, Vaugeois JM, Schiffmann SN, Pedrazzini T, El Yacoubi M, Vanderhaeghen JJ, Costentin J, Heath JK, Vassart G, Parmentier M. Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor. *Nature* 388: 674–678, 1997.
59. Lennon PF, Taylor CT, Stahl GL, Colgan SP. Neutrophil-derived 5'-adenosine monophosphate promotes endothelial barrier function via CD73-mediated conversion to adenosine and endothelial A2B receptor activation. *J Exp Med* 188: 1433–1443, 1998.
60. Levy BD, De Sanctis GT, Devchand PR, Kim E, Ackerman K, Schmidt BA, Szczeklik W, Drazen JM, Serhan CN. Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A(4). *Nat Med* 8: 1018–1023, 2002.
61. Licker M, de Perrot M, Spiliopoulos A, Robert J, Diaper J, Chevalley C, Tschopp JM. Risk factors for acute lung injury after thoracic surgery for lung cancer. *Anesth Analg* 97: 1558–1565, 2003.
62. Linden J. Adenosine in tissue protection and tissue regeneration. *Mol Pharmacol* 67: 1385–1387, 2005.
63. Linden J. Purinergic chemotaxis. *Science* 314: 1689–1690, 2006.
64. Lukashev DE, Smith PT, Caldwell CC, Ohta A, Apasov SG, Sitkovsky MV. Analysis of A2a receptor-deficient mice reveals no significant compensatory increases in the expression of A2b, A1, and A3 adenosine receptors in lymphoid organs. *Biochem Pharmacol* 65: 2081–2090, 2003.
65. Martin TR. Neutrophils and lung injury: getting it right. *J Clin Invest* 110: 1603–1605, 2002.
66. Milot J, Perron J, Lacasse Y, Letourneau L, Cartier PC, Maltais F. Incidence and predictors of ARDS after cardiac surgery. *Chest* 119: 884–888, 2001.
67. Morote-Garcia JC, Rosenberger P, Kuhlicke J, Eltzschig HK. HIF-1-dependent repression of adenosine kinase attenuates hypoxia-induced vascular leak. *Blood* 111: 5571–5580, 2008.
68. Morote-Garcia JC, Rosenberger P, Nivillac NM, Coe IR, Eltzschig HK. Hypoxia-inducible factor-dependent repression of equilibrative nucleoside transporter 2 attenuates mucosal inflammation during intestinal hypoxia. *Gastroenterology* 136: 607–618, 2009.
69. Novak I. ATP as a signaling molecule: the exocrine focus. *News Physiol Sci* 18: 12–17, 2003.
70. Ohta A, Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. *Nature* 414: 916–920, 2001.
71. Peng Z, Borea PA, Wilder T, Yee H, Chiriboga L, Blackburn MR, Azzena G, Resta G, Cronstein BN. Adenosine signaling contributes to ethanol-induced fatty liver in mice. *J Clin Invest* 119: 582–594, 2009.
72. Pinsky DJ, Broekman MJ, Peschon JJ, Stocking KL, Fujita T, Ramasamy R, Connolly ES Jr, Huang J, Kiss S, Zhang Y, Choudhri TF, McTaggart RA, Liao H, Drosopoulos JH, Price VL, Marcus AJ, Maliszewski CR. Elucidation of the thromboregulatory role of CD39/ectoapyrase in the ischemic brain. *J Clin Invest* 109: 1031–1040, 2002.
73. Reutershan J, Cagnina RE, Chang D, Linden J, Ley K. Therapeutic anti-inflammatory effects of myeloid cell adenosine receptor A2a stimulation in lipopolysaccharide-induced lung injury. *J Immunol* 179: 1254–1263, 2007.
74. Reutershan J, Vollmer I, Stark S, Wagner R, Ngamsri KC, Eltzschig HK. Adenosine and inflammation: CD39 and CD73 are critical mediators in LPS-induced PMN trafficking into the lungs. *FASEB J* 23: 473–482, 2009.
75. Robinson A, Keely S, Karhausen J, Gerich ME, Furuta GT, Colgan SP. Mucosal protection by hypoxia-inducible factor prolyl hydroxylase inhibition. *Gastroenterology* 134: 145–155, 2008.
76. Robson SC, Wu Y, Sun X, Knosalla C, Dwyer K, Enjyoji K. Ectonucleotidases of CD39 family modulate vascular inflammation and thrombosis in transplantation. *Semin Thromb Hemost* 31: 217–233, 2005.
77. Rosenberger P, Schwab JM, Mirakaj V, Masekowsky E, Mager A, Morote-Garcia JC, Unertl K, Eltzschig HK. Hypoxia-inducible factor-dependent induction of netrin-1 dampens inflammation caused by hypoxia. *Nat Immunol* 10: 195–202, 2009.
78. Rubenfeld GD, Caldwell E, Peabody E, Weaver J, Martin DP, Neff M, Stern EJ, Hudson LD. Incidence and outcomes of acute lung injury. *N Engl J Med* 353: 1685–1693, 2005.

79. Salvatore CA, Tilley SL, Latour AM, Fletcher DS, Koller BH, Jacobson MA. Disruption of the A(3) adenosine receptor gene in mice and its effect on stimulated inflammatory cells. *J Biol Chem* 275: 4429–4434, 2000.
80. Schwab JM, Chiang N, Arita M, Serhan CN. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. *Nature* 447: 869–874, 2007.
81. Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. *Nat Rev Immunol* 8: 349–361, 2008.
82. Serhan CN, Savill J. Resolution of inflammation: the beginning programs the end. *Nat Immunol* 6: 1191–1197, 2005.
83. Sharma AK, Linden J, Kron IL, Laubach VE. Protection from pulmonary ischemia-reperfusion injury by adenosine A2A receptor activation. *Respir Res* 10: 58, 2009.
84. Shorr AF, Abbott KC, Agadoa LY. Acute respiratory distress syndrome after kidney transplantation: epidemiology, risk factors, and outcomes. *Crit Care Med* 31: 1325–1330, 2003.
85. Silliman CC, Ambruso DR, Boshkov LK. Transfusion-related acute lung injury. *Blood* 105: 2266–2273, 2005.
86. Sitkovsky M, Lukashev D. Regulation of immune cells by local-tissue oxygen tension: HIF1 alpha and adenosine receptors. *Nat Rev Immunol* 5: 712–721, 2005.
87. Sitkovsky MV, Lukashev D, Apasov S, Kojima H, Koshiba M, Caldwell C, Ohta A, Thiel M. Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. *Annu Rev Immunol* 22: 657–682, 2004.
88. Sun CX, Young HW, Molina JG, Volmer JB, Schnermann J, Blackburn MR. A protective role for the A1 adenosine receptor in adenosine-dependent pulmonary injury. *J Clin Invest* 115: 35–43, 2005.
89. Sun CX, Zhong H, Mohsenin A, Morschl E, Chunn JL, Molina JG, Belardinelli L, Zeng D, Blackburn MR. Role of A2B adenosine receptor signaling in adenosine-dependent pulmonary inflammation and injury. *J Clin Invest* 116: 2173–2182, 2006.
90. Sun D, Samuelson LC, Yang T, Huang Y, Paliege A, Saunders T, Briggs J, Schnermann J. Mediation of tubuloglomerular feedback by adenosine: evidence from mice lacking adenosine 1 receptors. *Proc Natl Acad Sci USA* 98: 9983–9988, 2001.
91. Synnestvedt K, Furuta GT, Comerford KM, Louis N, Karhausen J, Eltzschig HK, Hansen KR, Thompson LF, Colgan SP. Ecto-5'-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. *J Clin Invest* 110: 993–1002, 2002.
92. Thiel M, Chouker A, Ohta A, Jackson E, Caldwell C, Smith P, Lukashev D, Bittmann I, Sitkovsky MV. Oxygenation inhibits the physiological tissue-protecting mechanism and thereby exacerbates acute inflammatory lung injury. *PLoS Biol* 3: e174, 2005.
93. Thompson LF, Eltzschig HK, Ibla JC, Van De Wiele CJ, Resta R, Morote-Garcia JC, Colgan SP. Crucial role for ecto-5'-nucleotidase (CD73) in vascular leakage during hypoxia. *J Exp Med* 200: 1395–1405, 2004.
94. Van Linden A, Eltzschig HK. Role of pulmonary adenosine during hypoxia: extracellular generation, signaling and metabolism by surface adenosine deaminase/CD26. *Exp Opin Biol Ther* 7: 1437–1447, 2007.
95. Volmer JB, Thompson LF, Blackburn MR. Ecto-5'-nucleotidase (CD73)-mediated adenosine production is tissue protective in a model of bleomycin-induced lung injury. *J Immunol* 176: 4449–4458, 2006.
96. Ware LB, Matthay MA. The acute respiratory distress syndrome. *N Engl J Med* 342: 1334–1349, 2000.
97. Weissmuller T, Campbell EL, Rosenberger P, Scully M, Beck PL, Furuta GT, Colgan SP. PMNs facilitate translocation of platelets across human and mouse epithelium and together alter fluid homeostasis via epithelial cell-expressed ecto-NTPDases. *J Clin Invest* 118: 3682–3692, 2008.
98. Yang D, Koupnova M, McCrann DJ, Kopeikina KJ, Kagan HM, Schreiber BM, Ravid K. The A2b adenosine receptor protects against vascular injury. *Proc Natl Acad Sci USA* 105: 792–796, 2008.
99. Yang D, Zhang Y, Nguyen HG, Koupnova M, Chauhan AK, Makitalo M, Jones MR, St Hilaire C, Seldin DC, Toselli P, Lamperti E, Schreiber BM, Gavras H, Wagner DD, Ravid K. The A2B adenosine receptor protects against inflammation and excessive vascular adhesion. *J Clin Invest* 116: 1913–1923, 2006.
100. Yang JN, Chen JF, Fredholm BB. Physiological roles of A1 and A2A adenosine receptors in regulating heart rate, body temperature, and locomotion as revealed using knockout mice and caffeine. *Am J Physiol Heart Circ Physiol* 296: H1141–H1149, 2009.
101. Yang Z, Day YJ, Toufektsian MC, Ramos SI, Marshall M, Wang XQ, French BA, Linden J. Infarct-sparing effect of A2A-adenosine receptor activation is due primarily to its action on lymphocytes. *Circulation* 111: 2190–2197, 2005.
102. Zarbock A, Ley K. The role of platelets in acute lung injury (ALI). *Front Biosci* 14: 150–158, 2009.
103. Zarbock A, Singbartl K, Ley K. Complete reversal of acid-induced acute lung injury by blocking of platelet-neutrophil aggregation. *J Clin Invest* 116: 3211–3219, 2006.
104. Zhou Y, Mohsenin A, Morschl E, Young HW, Molina JG, Ma W, Sun CX, Martinez-Valdez H, Blackburn MR. Enhanced airway inflammation and remodeling in adenosine deaminase-deficient mice lacking the A2B adenosine receptor. *J Immunol* 182: 8037–8046, 2009.